Cryoablation System Overview Cardiac Ablation for Atrial Fibrillation
The Arctic Front Advance™ Cardiac Cryoablation Catheter System includes the Arctic Front Advance™ Cryoballoon, which is used in conjunction with the CryoConsole, the FlexCath Advance™ Steerable Sheath, and the Achieve™ and Achieve Advance™ Mapping Catheters.
The Arctic Front Advance Cardiac Cryoablation Catheter is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. The cryoballoon has been used to treat over a quarter of a million patients in more than 50 countries worldwide.1 Findings from a large clinical trial found that the cryoballoon was a safe and effective treatment after drug failure.2
More detailed product information, including spec sheets, can be found on Medtronic Academy.
The Arctic Front Advance Cardiac Cryoablation Catheter uses cryo energy to isolate the pulmonary vein.
The FlexCath Advance Steerable Sheath helps deliver and position the Arctic Front Advance Cryoballoon in the left atrium.
The CryoConsole houses the coolant, electrical and mechanical components that run the catheters during a cryoablation procedure.
The Achieve and Achieve Advance Mapping Catheters are diagnostic catheters used to measure electrical signals before, during and after an ablation procedure.
The Freezor MAX Cardiac Cryoablation Catheter is a single-point catheter used to perform touch-up cryoablation to complete electrical isolation of the pulmonary veins as needed.
Designed with PVI in mind, the Arctic Front Advance Cryoballoon is an anatomical approach for PVI, creating long contiguous circumferential lesions surrounding the pulmonary vein.3 Providing physicians with a straightforward approach for PVI, the cryoballoon isolates each pulmonary vein with minimal energy applications, delivering consistent and predictable results.4
Watch the video below to see how the Arctic Front Advance Cryoballoon works.
Medtronic data on file
Packer DL, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(14): 1713-23.
Sarabanda AV, et al. Efficacy and safety of circumferential pulmonary vein isolation using a novel cryothermal balloon ablation system. J Am Coll Cardiol. 2005;46(10):1902-1912.
Providencia R., Defaye P., Lambiase P.D., Pavin D., Cebron J.-P., Halimi F., FAnselme R., Srinivasan N., Albenque J.-P., Boveda S. Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: Is cryoablation more reproducible? Europace. 2017;19(1):48-57.